Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Your search for esrd returned 14 results
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
This study raises important questions about the choice between lactated Ringer and saline.
A study found no significant increased risks for death or major adverse cardiac events among infected patients with established chronic kidney disease or end-stage kidney disease.
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.